A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

NCT03576469 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

CVI - Common Variable Immunodeficiency

Interventions

BIOLOGICAL: C1-esterase inhibitor [recombinant] (C1-INH-R)

Sponsor

IMMUNOe Research Centers